Cargando…
Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease
Parkinson’s disease (PD) is a predominantly idiopathic pathological condition characterized by protein aggregation phenomena, whose main component is alpha-synuclein. Although the main risk factor is ageing, numerous evidence points to the role of type 2 diabetes mellitus (T2DM) as an etiological fa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654753/ https://www.ncbi.nlm.nih.gov/pubmed/38027497 http://dx.doi.org/10.3389/fnins.2023.1244022 |
_version_ | 1785136693945303040 |
---|---|
author | Greco, Marco Munir, Anas Musarò, Debora Coppola, Chiara Maffia, Michele |
author_facet | Greco, Marco Munir, Anas Musarò, Debora Coppola, Chiara Maffia, Michele |
author_sort | Greco, Marco |
collection | PubMed |
description | Parkinson’s disease (PD) is a predominantly idiopathic pathological condition characterized by protein aggregation phenomena, whose main component is alpha-synuclein. Although the main risk factor is ageing, numerous evidence points to the role of type 2 diabetes mellitus (T2DM) as an etiological factor. Systemic alterations classically associated with T2DM like insulin resistance and hyperglycemia modify biological processes such as autophagy and mitochondrial homeostasis. High glucose levels also compromise protein stability through the formation of advanced glycation end products, promoting protein aggregation processes. The ability of antidiabetic drugs to act on pathways impaired in both T2DM and PD suggests that they may represent a useful tool to counteract the neurodegeneration process. Several clinical studies now in advanced stages are looking for confirmation in this regard. |
format | Online Article Text |
id | pubmed-10654753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106547532023-01-01 Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease Greco, Marco Munir, Anas Musarò, Debora Coppola, Chiara Maffia, Michele Front Neurosci Neuroscience Parkinson’s disease (PD) is a predominantly idiopathic pathological condition characterized by protein aggregation phenomena, whose main component is alpha-synuclein. Although the main risk factor is ageing, numerous evidence points to the role of type 2 diabetes mellitus (T2DM) as an etiological factor. Systemic alterations classically associated with T2DM like insulin resistance and hyperglycemia modify biological processes such as autophagy and mitochondrial homeostasis. High glucose levels also compromise protein stability through the formation of advanced glycation end products, promoting protein aggregation processes. The ability of antidiabetic drugs to act on pathways impaired in both T2DM and PD suggests that they may represent a useful tool to counteract the neurodegeneration process. Several clinical studies now in advanced stages are looking for confirmation in this regard. Frontiers Media S.A. 2023-11-03 /pmc/articles/PMC10654753/ /pubmed/38027497 http://dx.doi.org/10.3389/fnins.2023.1244022 Text en Copyright © 2023 Greco, Munir, Musarò, Coppola and Maffia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Greco, Marco Munir, Anas Musarò, Debora Coppola, Chiara Maffia, Michele Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title | Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title_full | Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title_fullStr | Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title_full_unstemmed | Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title_short | Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease |
title_sort | restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in parkinson’s disease |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654753/ https://www.ncbi.nlm.nih.gov/pubmed/38027497 http://dx.doi.org/10.3389/fnins.2023.1244022 |
work_keys_str_mv | AT grecomarco restoringautophagicfunctionacasefortype2diabetesmellitusdrugrepurposinginparkinsonsdisease AT muniranas restoringautophagicfunctionacasefortype2diabetesmellitusdrugrepurposinginparkinsonsdisease AT musarodebora restoringautophagicfunctionacasefortype2diabetesmellitusdrugrepurposinginparkinsonsdisease AT coppolachiara restoringautophagicfunctionacasefortype2diabetesmellitusdrugrepurposinginparkinsonsdisease AT maffiamichele restoringautophagicfunctionacasefortype2diabetesmellitusdrugrepurposinginparkinsonsdisease |